What We Offer
Our Products
Healgen Combo
Product Overview
Healgen combo SARS-CoV-2/Flu A+B Rapid Antigen Point-of-Care Test is a lateral flow immunoassay intended for in vitro rapid, simultaneous qualitative detection and differentiation of nucleocapsid antigen from SARS-CoV-2, influenza A and influenza B directly from anterior nasal swab specimens obtained from patients who are suspected of COVID-19 by their healthcare provider, within the first five days of onset of symptoms.
- SARS-CoV-2/Flu A+B Rapid POC Combo Antigen Test
- Simultaneous testing for acute respiratory infections caused by COVID-19, Flu A, Flu B
- Lateral flow immunoassay
- Covid-19: Sensitivity 92.0%; Specificity 99.0%
- Flu A: Sensitivity 92.5%; Specificity 99.9%
- Flu B: Sensitivity 90.5%; Specificity 99.9%
- Nasal swab samples
- Delivers results within 15 minutes
- No equipment necessary
- CLIA Waived Test
RCS Healthcare: Our Vision